Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: wonk who wrote (2781)	7/8/1998 8:37:00 AM
From: dwlima	Respond to of 5402

the book i mentioned provides a good overview of the DCF method, but does not delve into detail nor provide a good understanding of other valuation methods. so, this is a good opportunity for me to read about the merits of other valuation techniques. although as i said -I am not an analyst- this topic does interest me. Your recommendation for book(s) are welcome. I wrote to a friend 2 nights ago that has his MBA from Wharton. When i told him that Biotech companies discount earnings intead of cash flow, he was surprised. He also wanted to know why. so, i will read any books you think are worthy of reading and e-mail my professor about the topic. once i have read up more on the earnings method and others, we can have an informative, exchange of info. via PM. I have to say that people are not always as edgy as they seem. if i question a method and receive a response like- i am surprised you have not come across blah, blah, blah- it can be taken in the offensive. So, how about SGNC. A little more volume yesterday and most of it on the buy side. I hear we will see some nice surprises soon. I figure that if SGNC carves out .5% or 0.005 of the $20-30 billion market (not including the larger market that may result from the product and others like it)- they would have revenues of $125 million. so, even at 1x sales, we have a share price of $6. a larger market, a strong suitor, etc. puts this stock way ahead of that price. what do you think?